AE	adverse events
AFP	alpha-foetoprotein
Anti-VEGFR	anti-vascular endothelial growth factor
BCLC	Barcelona Clinic Liver Cancer
BSC	best supportive care
CP	Child–Pugh
DCR	disease control rate
ECOG	Eastern Cooperative Oncology Group
FGFR	fibroblast growth factor receptor
HCC	hepatocellular carcinoma
HBV	hepatitis B virus
HCV	hepatitis C virus
HR	hazard ratio
ICIs	immune checkpoint inhibitors
IO	immuno-oncology
IT	immunotherapy
NE	not evaluated
OR	odds ratio
ORR	overall response rate
OS	overall survival
PFS	progression-free survival
PDGFR	platelet-derived growth factor receptor
PPES	palmar–plantar erythrodysaesthesia syndrome
PS	performance status
PVA	portal venous area
PVV	portal venous flow velocity
QALY	quality-adjusted life years
TACE	transarterial chemoembolisation
TEAEs	treatment-emergent adverse events
TTP	time to progression
TKIs	tyrosine kinase inhibitors
RECIST	response evaluation criteria in solid tumours